^
    Back
    Association details:
    Biomarker:NTRK2 fusion
    Cancer:Solid Tumor
    Drug:SIM1803-1A (ROS1 inhibitor, Trk inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASCO 2020
    Title:

    Preclinical evaluation of SIM1803-1A, a small molecule Trk/ROS1 dual inhibitor for wild and mutate NTRK/ROS1 fusion solid malignancies.

    Published date:
    05/28/2020
    Excerpt:
    ...studies have shown SIM1803-1A is a potent Trk/ROS1 dual inhibitor with better safety potentially from improved kinase selectivity….SIM1803-1A is currently at IND submission stage and represents a promising clinical candidate for the treatment-naïve and acquired-resistance NTRK/ROS1 fusion-positive malignancies.
    DOI:
    10.1200/JCO.2020.38.15_suppl.e21663